MRSA
Learn about MRSA diagnosis, including clinical documentation requirements, medical coding (ICD-10-CM codes), and healthcare guidelines for Methicillin-resistant Staphylococcus aureus infections. Find information on MRSA screening, treatment, and infection control practices relevant to physicians, nurses, and other healthcare professionals. This resource provides details on appropriate terminology for accurate MRSA documentation and coding for optimal reimbursement and epidemiological tracking.
Methicillin-resistant Staphylococcus aureus infection, a difficult-to-treat bacterial infection.
Skin infection (red, swollen, painful, pus-filled boils), fever, chills, sometimes pneumonia.
Hospitals, nursing homes, gyms, contaminated surfaces, skin-to-skin contact.
ICD-10 Code Families
Complete code families applicable to A49.02
When to use each related code
| Description | When to use |
|---|---|
| Methicillin-resistant S. aureus infection | Confirmed S. aureus infection resistant to methicillin. Use additional codes for infection site. |
| Staphylococcus aureus bacteremia | S. aureus identified in bloodstream. Include methicillin resistance status (e.g., MRSA) if known. |
| Soft tissue infection | Infection involving skin, subcutaneous tissue, fascia. Specify organism if known (e.g., MRSA). |
Best-practice checklist
- ✓MRSA diagnosis confirmation method (PCR, culture)
- ✓Specific body site of MRSA infection
- ✓Antibiotic susceptibility testing results
- ✓Prior MRSA colonization or infection history
- ✓Clinical manifestations and symptoms of infection
Common pitfalls to avoid
Coding MRSA without specifying the infection site (e.g., skin, pneumonia) leads to inaccurate severity and reimbursement.
Miscoding MRSA colonization (present but not causing illness) as infection impacts quality metrics and antibiotic stewardship.
Insufficient documentation supporting MRSA diagnosis creates audit risks for claims denials and compliance issues.
Best-practice tips
- 01Document MRSA risk factors: prior infections, recent hospitalizations.
- 02Code accurately: Use ICD-10-CM codes for MRSA and related conditions.
- 03Ensure complete CDI: Specify infection site, type (e.g., CA-MRSA, HA-MRSA).
- 04Follow infection control protocols: Adhere to hand hygiene, isolation guidelines.
- 05Monitor antibiotic resistance: Track local patterns, adjust treatment accordingly.
Step-by-step checklist
- 1
Purulent skin infection or SSTI present?
- 2
Risk factors for MRSA (e.g., recent hospitalization, IVDU)?
- 3
Positive MRSA culture or PCR?
- 4
Consider local MRSA prevalence in diagnosis.
- 5
Document all findings supporting MRSA diagnosis.
Ready-to-paste narrative
Patient presents with signs and symptoms suggestive of Methicillin-resistant Staphylococcus aureus (MRSA) infection. Presenting complaint includes [specific complaint, e.g., localized skin abscess, wound infection, pneumonia, bacteremia]. Onset of symptoms occurred [timeframe]. Physical examination reveals [objective findings, e.g., erythema, warmth, swelling, purulent drainage, induration, fever, elevated heart rate, respiratory distress]. Location of infection is [site of infection, e.g., left lower extremity, right upper lobe, surgical site]. Patient history includes [relevant medical history, e.g., recent hospitalization, antibiotic use, diabetes, immunocompromised status]. Differential diagnoses considered include cellulitis, soft tissue infection, pneumonia, sepsis, and other bacterial infections. Laboratory studies ordered include wound culture, blood culture, complete blood count (CBC) with differential, and comprehensive metabolic panel (CMP). Preliminary diagnosis of MRSA infection is made based on clinical presentation. Empiric antibiotic therapy initiated with [antibiotic name and dosage] pending culture and sensitivity results. Patient education provided regarding wound care, hygiene, infection control measures, and medication adherence. Follow-up scheduled for [date/time] to assess treatment response and adjust therapy based on culture results. ICD-10 code [appropriate ICD-10 code, e.g., A49.02, L03.115, J15.212] is assigned, reflecting the specific site and type of MRSA infection. CPT codes for evaluation and management (E/M) services, as well as any procedures performed, will be documented and coded appropriately, e.g., 99203, 99214, 10060, I&D. This documentation supports medical necessity for services rendered and accurate healthcare billing.
Common questions and answers
What are the most effective evidence-based treatment strategies for recurrent MRSA skin and soft tissue infections in adults?+
Recurrent MRSA skin and soft tissue infections (SSTIs) in adults present a significant clinical challenge. Effective treatment involves a multifaceted approach. First, thorough source control, including incision and drainage of abscesses, is crucial. Empiric antibiotic therapy should be guided by local resistance patterns but often includes options like doxycycline, trimethoprim-sulfamethoxazole (TMP-SMX), or clindamycin for outpatient oral therapy. For severe infections or those failing oral therapy, intravenous vancomycin, linezolid, or daptomycin are recommended. Decolonization strategies, such as intranasal mupirocin and chlorhexidine body washes, play a vital role in reducing recurrence. Patient education on hygiene practices and wound care is also essential. Furthermore, consider screening household contacts for MRSA carriage. Explore how combination therapies and newer agents are being investigated for persistent cases. Consider implementing a standardized protocol for managing recurrent MRSA SSTIs in your practice.
How can clinicians differentiate between MRSA colonization and infection, and what are the appropriate management strategies for each?+
Distinguishing between MRSA colonization and infection is key to appropriate management. MRSA colonization implies the presence of the bacteria without associated symptoms or signs of infection. In contrast, MRSA infection presents with clinical manifestations like cellulitis, abscesses, pneumonia, or bloodstream infections. Colonization typically does not require antibiotic treatment, focusing instead on preventing its spread through proper hand hygiene and contact precautions. Infection, however, necessitates targeted antibiotic therapy based on the site and severity, often including agents like vancomycin, linezolid, or daptomycin. Accurate diagnosis involves clinical assessment, cultures, and sometimes imaging studies. Learn more about the latest guidelines for MRSA screening and decolonization practices to optimize patient outcomes and reduce the risk of transmission.
What are the emerging rapid diagnostic tests for MRSA in the clinical setting, and how do they compare to traditional culture methods in terms of sensitivity, specificity, and turnaround time?+
Rapid diagnostic tests (RDTs) for MRSA are increasingly used to expedite diagnosis and guide therapy. These tests, including polymerase chain reaction (PCR) and other molecular assays, offer significantly faster turnaround times compared to traditional culture methods, often providing results within hours rather than days. While traditional cultures remain the gold standard for sensitivity and specificity, some RDTs demonstrate comparable performance, particularly for detecting MRSA in nasal swabs for colonization screening. However, the sensitivity and specificity of various RDTs can vary. Clinicians should carefully consider the performance characteristics of the specific RDT being used, the clinical context, and local prevalence of MRSA when interpreting results. Explore how these rapid tests can improve antimicrobial stewardship by enabling earlier targeted therapy and reducing the unnecessary use of broad-spectrum antibiotics.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.